Symrise and Probi showcase joint health portfolio at SupplySide Global 2026
Daily supplementation with 600 mg of Acerowell for 12 weeks significantly improved skin radiance and translucency compared with a placebo, according to clinical data presented by Symrise at SupplySide Global 2026 in Las Vegas. The randomized, placebo-controlled study involved 108 women aged 45 to 60. More than 80% of participants also reported improvements in skin luminosity, complexion, and texture.
Integration of Health Active Solutions and Probi portfolios in Las Vegas
At booth #2364, the Care & Wellness Division of Symrise is showcasing its Health Active Solutions and Probi portfolios together for the first time in the Americas. Isabelle Ducellier, Global VP Health at Symrise Care & Wellness, stated that the joint presence combines health actives, biotics, and formulation expertise to turn strong science into differentiated solutions for customers and consumers. The integrated exhibit connects natural health actives, biotics, and clinical research for human and pet health markets.
The showcase features science-backed ingredients spanning beauty-from-within, microbiome health, and targeted nutrition. Manufacturers can explore formulation concepts, recipes, and taste-balancing solutions for beverages, stick packs, and chewables. The joint display addresses growing market demands across women’s health, longevity, digestive health, and sports and active nutrition.
Clinical findings for postbiotic Rham271h and digestive strains
Probi’s Rham271h postbiotic, derived from Lacticaseibacillus rhamnosus 6594, demonstrates how inactivated microorganisms provide an alternative to live probiotics. The ingredient retains biological activity while offering resistance to heat and pH changes. In vitro research indicates effects on immune-related biomarkers, including increased levels of the anti-inflammatory cytokine IL-10, alongside support for gut barrier integrity. Suggested at a daily dose of 10 billion TFU, Rham271h suits dietary supplements, functional foods, and beverages.
In digestive health, new clinical data for LP299V and LPGOS42 support Probi’s strain-specific approach. An eight-week randomized, placebo-controlled study of 100 healthy adults with occasional constipation found that the dual-strain combination significantly improved digestive comfort, regularity, and quality-of-life outcomes compared to a placebo. A post-hoc analysis of participants reporting three or fewer bowel movements per week at baseline showed a significantly greater increase in weekly complete spontaneous bowel movements with the dual-strain formulation.
Frequently asked questions about the SupplySide Global 2026 showcase
What dosage of Acerowell was used in the clinical study?
Participants in the randomized, placebo-controlled trial took a daily dose of 600 mg of Acerowell for 12 weeks.
What bacterial strain is Probi’s Rham271h derived from?
Rham271h is derived from Lacticaseibacillus rhamnosus 6594 as an inactivated postbiotic ingredient.
Where is Symrise exhibiting its Care & Wellness portfolio?
Symrise is showcasing its combined portfolio at booth #2364 during SupplySide Global 2026 in Las Vegas.
Worth a look